Elbert Huang to Quality-Adjusted Life Years
This is a "connection" page, showing publications Elbert Huang has written about Quality-Adjusted Life Years.
Connection Strength
1.370
-
The cost-effectiveness of improving diabetes care in U.S. federally qualified community health centers. Health Serv Res. 2007 Dec; 42(6 Pt 1):2174-93; discussion 2294-323.
Score: 0.266
-
Cost-effectiveness of Shared Telemedicine Appointments in Young Adults With T1D: CoYoT1 Trial. Diabetes Care. 2019 08; 42(8):1589-1592.
Score: 0.148
-
Cost-effectiveness of Initiating an Insulin Pump in T1D Adults Using Continuous Glucose Monitoring Compared with Multiple Daily Insulin Injections: The DIAMOND Randomized Trial. Med Decis Making. 2018 11; 38(8):942-953.
Score: 0.142
-
Individualized Glycemic Control for U.S. Adults With Type 2 Diabetes: A Cost-Effectiveness Analysis. Ann Intern Med. 2018 02 06; 168(3):170-178.
Score: 0.133
-
Cost-effectiveness of MODY genetic testing: translating genomic advances into practical health applications. Diabetes Care. 2014; 37(1):202-9.
Score: 0.099
-
Impact of delaying blood pressure control in patients with Type 2 diabetes: results of a decision analysis. J Gen Intern Med. 2012 Jun; 27(6):640-6.
Score: 0.088
-
The public health implications of the cost-effectiveness of bariatric surgery for diabetes. Diabetes Care. 2010 Sep; 33(9):2126-8.
Score: 0.081
-
The cost-effectiveness of continuous glucose monitoring in type 1 diabetes. Diabetes Care. 2010 Jun; 33(6):1269-74.
Score: 0.078
-
The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes. Diabetes Care. 2006 Feb; 29(2):259-64.
Score: 0.059
-
Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults. JAMA Health Forum. 2025 Mar 07; 6(3):e245586.
Score: 0.055
-
The Impact of Unrelated Future Medical Costs on Economic Evaluation Outcomes for Different Models of Diabetes. Appl Health Econ Health Policy. 2024 Nov; 22(6):861-869.
Score: 0.053
-
First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study. Ann Intern Med. 2022 10; 175(10):1392-1400.
Score: 0.047
-
Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis. Gynecol Oncol. 2021 08; 162(2):249-255.
Score: 0.042
-
Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis. Am J Gastroenterol. 2021 01 01; 116(1):125-133.
Score: 0.041
-
The Impact of Biomarker Screening and Cascade Genetic Testing on the Cost-Effectiveness of MODY Genetic Testing. Diabetes Care. 2019 12; 42(12):2247-2255.
Score: 0.038